POST Online Media Lite Edition



 

Merck considers sale of consumer health business

Staff Writer |
Merck KGaA is considering selling its $1 billion consumer health unit to meet its financial targets as a decline in its liquid crystal business forces it to review its strategy.

Article continues below






"We expect increasing internal constraints to fund the business to reach the required scale. Fully anticipating this, we are preparing strategic options," Belen Garijo, chief executive of the healthcare business, said in a statement.

"Any possible proceeds from a potential transaction would be used to deliver on the company’s overall financial targets."

Merck said it would consider a full or partial sale of the consumer health business as well as strategic partnerships, adding that the review process was in an early stage with no final decision taken.

Merck, which traces its roots to a 17th century pharmacy, is focusing on its pharmaceuticals unit, where it is pinning growth hopes on cancer immunotherapy treatment Bavencio and multiple sclerosis pill Mavenclad after a string of setbacks.

It has also built a global biotech laboratory supplies business with takeovers of Millipore and Sigma-Aldrich in 2010 and 2016.


What to read next

Sigma-Aldrich to sell solvents and inorganics business
Merck solves Vioxx class action, will pay $830 million
Merck and Pfizer together against type 2 diabetes